Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03969550|
Recruitment Status : Completed
First Posted : May 31, 2019
Last Update Posted : May 31, 2019
Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial.
The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.
|Condition or disease||Intervention/treatment|
|AIDS Progressive Multifocal Leucoencephalopathy (PML)||Other: Measure of overall survival|
|Study Type :||Observational|
|Actual Enrollment :||34 participants|
|Official Title:||Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?|
|Actual Study Start Date :||January 2008|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
- Other: Measure of overall survival
Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
- Overall survival (OS) [ Time Frame: 8 years ]